Announcement: Yellow Fever Vaccine Access
Sanofi Pasteur, the manufacturer of the only yellow fever vaccine (YF-Vax) licensed in the United States, has announced that YF-Vax will be unavailable from mid-2017 to mid-2018 because of delays in the production process. Sanofi Pasteur applied and received approval from the US Food and Drug Administration (FDA) to make another yellow fever vaccine available in the United States under an investigational new drug (IND) program.* Manufactured by Sanofi Pasteur in France, this vaccine, Stamaril, is registered and distributed in more than 70 countries. It is comparable in safety and efficacy to YF-Vax (see the yellow fever vaccine information sheet).
In order to meet the requirements of the IND program, Sanofi Pasteur can provide Stamaril to only a limited number of clinics. Sanofi has identified sites throughout the United States to include in the program so patients can have continued access to yellow fever vaccine.
Once YF-Vax is no longer available, travelers and health care providers will be able to find locations that can administer Stamaril by visiting the yellow fever vaccination clinic search page. For information about which countries require yellow fever vaccination for entry and which countries the CDC recommends yellow fever vaccination, visit the CDC Travelers’ Health website (www.cdc.gov/travel).
*Although the name of the FDA program is "investigational new drug," Stamaril is not investigational or experimental. Stamaril has been used in European and other countries for decades but is not licensed in the United States. IND is the mechanism through which FDA gives approval for Stamaril to be imported.
- Page created: April 18, 2017
- Page last updated: April 18, 2017
- Page last reviewed: April 18, 2017
- Content source: